Although viable gene therapy based methods have been reported for the selective removal or purging of contaminating epithelial derived cancer cells from stem cell grafts, similar strategies for the purging of leukemia cells have been significantly less efficient. Hematopoietic cells are difficult targets for transduction with currently available vectors. Polylysine based molecular conjugate vectors (MCV) were previously found to effectively transduce both normal and malignant hematopoietic cells. A panel of human leukemia cell lines as well as CD34 þ selected primary human hematopoietic progenitor cells (HPC) were tested for differential gene expression utilizing different promoters. Reporter gene expression under the control of RSV and SV40 promoters showed a 6-log fold increase in leukemia cells when compared to primary HPC. Using a polylysine based recombinant molecular conglomerate vector (recMCV) encoding the HSV-tk suicide gene under control of RSV, we demonstrated effective and specific cell killing in all leukemia cell lines as well as in primary human leukemia cells derived from chemotherapy refractory patients, while HPC survived under the same conditions at approximately 20% viability. These proof of principle experiments demonstrate that gene therapy technology could be utilized to successfully purge leukemia cells from HPC.
F or many patients suffering from hematologic malignancies, the only hope for a cure or for long-term survival is an allogeneic bone marrow transplantation (allo-BMT). However, only a fraction of patients in need of this procedure will undergo it because biological constraints preclude this form of treatment. These include the lack of a matched donor, advanced age (455 years), and other comorbid conditions commonly seen in pretreated cancer patients. In contrast, these limitations are less relevant with autologous BMT (auto-BMT), as a donor is not required and this treatment is much better tolerated.
However, for most recurrent myeloid leukemias, auto-BMT at present is considered inadequate for achieving a cure or a durable disease remission. 1 The three main reasons for the higher rate of disease relapse following auto-BMT compared to allo-BMT are: first, the lack of a graft vs. leukemia effect (GVL) with auto-BMT second, residual contaminating tumor cells remain in autologous stem cell preparations and third leukemia cells surviving the conditioning regimen. 1 Nevertheless, in some studies comparing auto-BMT and allo-BMT, survival was found to be almost identical. 2 This is explained with the increased procedure-related mortality associated with allo-BMT, particularly graft vs. host disease. 3, 4 Therefore, it is reasonable to pursue strategies aiming to enhance the therapeutic efficacy of auto-BMT to replace the more toxic allo-BMT. One focus of transplant research is immunotherapy, which aims to induce a GVL effect after auto-BMT. 4 Another strategy pursues the development of purging procedures to more effectively reduce residual tumor burden in stem cell grafts. Gribben et al 5 has shown that the reduction of tumor cells in autologous grafts to molecular nondetection in patients with B-cell lymphoma correlates with improved survival. Miller et al 6 showed a survival benefit in AML patients who underwent auto-BMT with 4-hydroperoxycyclophosphamide purged stem cells vs. transplantation with an untreated graft. Despite supporting data from randomized clinical trials, the concept of purging remains controversial. 7, 8 Nevertheless, it is well accepted that more effective purging techniques could profoundly impact survival.
Here, we describe a gene-therapy based bone marrow purging system that can selectively eliminate contaminating leukemia cells from human hematopoietic progenitor (HPC) cultures while preserving viability of human progenitor cells. Previous studies utilizing gene transfer for purging of human stem cells have successfully used adenovirus to eliminate breast cancer cells. [9] [10] [11] Breast cancer cells are permissive to adenovirus infection while hematopoietic cells are not, because hematopoietic cells do not express or only minimally express the coxsackie adenovirus receptor (CAR). 10, 12, 13 Therefore, although previously reported adenovirus-purging strategies are viable for CAR positive cancers, they would not be successful for the purging of leukemia cells. We have previously reported that the formation of polylysinebased molecular conjugate vectors (MCV) and recombinant molecular conglomerate vectors (recMCV) achieve effective transduction of different leukemia cells at a very high efficiency and also CD34 þ selected primary human bone marrow cells. 12, 14 Similarly, an adenovirus with lysine modified fiber protein was found to efficiently transduce primary myeloma. 12, 15 The goal of this study was to investigate whether polylysine based vector systems are suitable for the purging of leukemia cells from human HPCs. Different promoters were tested to study whether differential gene expression can be achieved in normal and malignant hematopoietic tissue.
Methods

Construction of the MCV and recMCV
Construction of plasmid expression vectors. The plasmid pACCMVpLpASR( þ ) (generous gift of Dr Robert Gerard, UT Southwestern, Dallas, TX) was used to generate different expression plasmids under control of the CMV, RSV and SV40 promoters. Plasmid pACCMVLuc has been previously described. 16 Construction of the plasmid pACRSVLuc. The RSV promoter was obtained from the plasmid pRC/RSV (invitrogen) using BglII and HindIII restriction digestion. The 594 bp RSV promoter fragment was inserted into the BglII and HindIII digested pGL3 promoter vector (Promega) to generate the plasmid pGL3RSV. The 2.5 kb fragment containing the RSV-Luciferase-SV40 PA (poly A) cassette was obtained from the plasmid pGL3RSV by restriction enzyme digestion with BglII/ BamHI. This cassette and the NotI digested backbone of pACCMVpLpASR( þ ) were blunt ended with deep vent polymerase (New England Biolabs). The expression cassette was ligated into the vector backbone with ''quick ligation'' (New England Biolabs).
Construction of the plasmid pACSV40Luc. The 2.1 kb SV40-Luciferase-SV40 PA expression cassette was removed from the pGL3 promoter by restriction enzyme digestion with BglII and BamHI. The cassette was inserted into the NotI digested backbone of pACCMVpLpASR( þ ) using blunt end ligation and ampicillin selection of recombinant clones.
Recombinant adenovirus propagation. Recombinant adenovirus AdCMVLuc (control virus) and AD.RSVtk were constructed as previously described, to generate recMCVLuc and recMCVtk, respectively. 17, 16 Adenovirus dl312 for the construction of MCV was a generous gift of Dr Thomas Shenk, Princeton, NJ. 18 Adenoviruses were propagated on 911 or 293 cells using endotoxin free conditions and CsCl density purification as previously described. 16, 19 Virus preps were screened for replication competent adenovirus by propagation on A549 cells. This assay has a sensitivity of 1 contaminant per 10 8 PFU. All viral preps had a PFU: particle ratio of o100:1. All lots of recombinant adenovirus contained less than 1 endotoxin unit/ml as measured by the limulus amebocyte lysate assay (Bio Whittaker).
Construction and quality control of the MCV and recMCV. Polylysine based MCV and recMCV were synthesized and assembled as previously reported by our group using the heterobifunctional linker EDC (Pierce) to link adenovirus and poly-L-lysine (Sigma). 12, 20 Details on production as well as quality control were also published in a dedicated methodology book chapter. 21 Following further CsCl purification of the conjugated product, the vector conjugtate was analyzed for adenoviral particle content using optic densitometry at 210 nm. The vector volume was adjusted to a viral particle number of 5 Â 10 6 contained in 10 ml of vector solution.
Plasmid DNA or salmon sperm DNA was employed to assemble the MCV and recMCV, respectively. To achieve reproducible electrostatic charges of the vector complex for each vector lot produced, vector lots were standardized by their ability to migrate in an electric field by using electrophoresis as previously published. 12 Electrostatic charges were normalized between lots by complexing positively charged vector with negatively charged DNA. All plasmid DNA was purified to remove endotoxin with commercial Qiagen plasmid preparation kits and effective removal was confirmed using the limulus amebocyte lysate assay (Bio Whittaker, Walkersville, MD). Finally, each lot of vectors was standardized using a published bioassay. 21 Briefly, each lot of MCV at a particle number of 0.2 was required to reproducibly achieve at least 75% transduction of a HeLa monolayer plated at 80% confluence. For most hematopoietic cell gene transfer studies, we determined the optimal viral particle number of the vector construct to be 10 per cell.
Cells and cell transfections
Media for all cells were supplemented with penicillin/ streptomycin (P/S) (Cellgro Mediatech, Herndon, VA). These cells were maintained at 371C under a 5% CO 2 atmosphere in a humidified incubator. The human embryonic kidney cell 293 line and human retinoblastoma cell line 911 were cultured in DMEM (Gibco-Life Technologies, Gaithersburg, MD) and supplemented with a 10% fetal bovine serum (FBS) (Gibco-Life Technologies). Human leukemia cell lines (the factor dependent megakaryoblastic MO7-e, MBO2 and Meg-01); the acute monocytic leukemia cell lines THP1 and U937, TF1, KG1, the erythroblastic leukemia cell line K562 and primary human HPC cells were grown in RPMI (Gibco) supplemented with 10% FBS (Hyclone, Logan, Utah). Meg-01, MBO2 and MO7e cells were cultured with rhGM-CSF (10 ng/ml). Primary hematopoietic stem cell cultures were supplemented with rhSCF (30 ng/ml) and rhIL-6 (30 ng/ml) Peprotech (Rocky Hill, NJ).
Primary human hematopoietic cells were obtained from volunteers and leukemia cells from patients following protocols approved by the Institutional Review Board of LSUHSC. Bone marrow cells were obtained through standard aspiration from the iliac crest of normal donors. Peripheral blood stem cells were obtained by cytapheresis of the mononuclear fraction after G-CSF stimulation. All cells were collected in MyeloCult H5100 medium (StemCell Technologies, Vancouver, BC), and supplemented with 250 U/ml heparin. For erythrocyte lysis, specimens were incubated for 1 minute in 0.747% NH 4 Cl solution and further purified using a Ficoll gradient. Purification and selection for CD34 expressing cells was carried out using the Cellpro System, SEPRATE SC (stem cell concentration system) (Bothell, WA). Flow cytometric analysis was performed for CD34 antigen expression using a directly conjugated PE HPCA-II-CD34 monoclonal antibody (Becton Dickinson, San Jose, CA), directly conjugated FITC-CD45 antibody (BeckmanCoulter, Hialeah, FL), and 7-AAD (7-amino-actinomycin-D, Molecular Probes, Eugene, Oregon) for viability (FacsCalibur Flow cytometer, Becton Dickinson). Following selection, all primary human cells were aliquoted and cryopreserved in liquid nitrogen and used after being thawed once.
Primary human leukemia cells were obtained through cytapheresis from patients with the medical indication for that procedure. One patient had been suffering from chronic myelogenous leukemia (CML) and after a series of preceding chemotherapies had progressed to blast crisis (CML-Blast), when she required cytapheresis. Another patient with acute lymphocytic leukemia, after having initially achieved a complete remission, was admitted with disease relapse despite having been in the maintenance phase of his chemotherapy treatment for over 1 year (ALL).
Cell transfections were performed as previously described using MCV and recMCV constructs. 12, 20 Briefly, 1 Â 10 6 cells were suspended in Eppendorf tubes in the above described culture conditions. Vector was then added to achieve a total volume of 200 ml. The sample tubes were incubated for 2 hours at 371C under rotation. Following that transfection step, cells were washed to remove excess vector and placed back into normal culture conditions. Ganciclovir was added at a concentration of 50 mmol and cells were exposed for 72 hours.
22-24
Construction of EGFP expressing leukemia cell lines
Construction, expansion and purification of the EGFP expressing retrovirus has been described previously. 25 Amphotropic retrovirus was harvested from the supernatant of the packaging cell line RetroPack PT67 (Clontech). For retrovirus transduction, Meg-01, KG1, MO7e and THP1 cells were incubated in six-well plates at a multiplicity of infection of 10 in serum reduced conditions (2%) for 6 hours. G418 was used to select transduced cells. Single-cell clones were later selected for further expansion. Successful retrovirus transduction and selection was confirmed by flowcytometry, where 100% of cells were found to express EGFP. All selected cell clones maintained a stable level of 100% transgene expression after withdrawal of G418.
Assays for determining cytotoxicity and discrimination of normal from leukemia cells
Cytotoxicity assays were performed by trypan blue exclusion staining and independently confirmed by 7-AAD staining followed by flowcytometric analysis. Scoring for EGFP expressing cells in mixed culture was performed by flow cytometry (Facscalibur, Becton and Dickinson, Franklin Lakes, NJ) or for cell colonies cultured in semisolid agar by using ultraviolet light transmission microscopy to identify genetically marked, green fluorescing leukemia cells (Nikkon TE 300). Colony forming assays in semisolid agar were conducted to determine presence of leukemia cells and their ability to form colonies (CFU-L). Colony forming assays for normal human hematopoiesis (CFU-GM, GEMM) were performed as previously described by using premade methylcellulose media with lineage specific factor supplementation (StemCellTechnologies, Vancouver, BC). 26 
Data and statistical analysis
For all samples, statistical significance of differences was performed with Student's t-test, which was provided within a statistical software program (Sigma Plot; SPSS Science, Chicago, IL). Values of Po.05 were assumed for statistical significance.
Results
Differential transgene expression can be achieved between human leukemia cells and primary human hematopoietic stem cells under control of the RSV or SV40 promoters A previously described MCV was employed to evaluate transgene expression with different promoters (CMV, RSV, SV40) in a panel of different leukemia cell lines and to compare gene expression levels to primary, CD34 þ selected human HPCs. 12, 20, 27 The transfection conditions for this polylysine-based vector can be adjusted to achieve nearly 100% transduction efficiency in both human leukemia cell lines and in human primary HPC. 12 For each individual experiment, complete transduction efficiency was validated using an EGFP construct and flowcytometry (data not shown). 1 Â 10 6 cells were transduced with MCV and assembled with different luciferase expression plasmids (pACCMVLuc, pACRSVLuc, pACSV40Luc). The means of quadruplicate gene expression levels7SEM were plotted as relative light units divided by total protein (RLU/protein) and are depicted in Figure 1 . Significant levels of luciferase gene expression were found in all cell lines including primary cells following transfection with the CMV promoter driven construct. Compared to the CMV promoter driven construct, RSV or SV40 controlled transgene expression was reduced by approximately one-and two-log fold, in all leukemia cell lines, respectively. However, when compared to CMV, virtually no luciferase gene expression was detected in primary human HPC after transfection with RSV or SV40 driven constructs. Moreover, there was no significant difference in the expression characteristics between bone marrow and peripheral blood CD34 þ selected progenitor cells. These results indicate that both RSV and SV40 controlled genes delivered with MCV can be differentially expressed in normal and malignant hematopoietic cells.
recMCV encoding the HSV-tk suicide gene (recMCVtk) delivers specific and effective cytotoxicity to a panel of human leukemia cells
The RSV promoter using the HSVtk suicide gene was selected for further development of a purging strategy. We previously reported that polylysine based recMCV have significantly enhanced gene expression properties over MCV. 20 A recMCV vector was developed to encode the HSVtk gene under control of the RSV promoter. To test whether the construct could effectively kill human leukemia cells, dose-response experiments were conducted. First, the acute vector related toxicity was evaluated. Acute vector related cytotoxicity was determined by viability assays using 7-AAD staining with flowcytometry. Percent viability was plotted against adenovirus vector particles complexed in the conjugate (Fig 2a and b) . The data demonstrate that the vector by itself confers direct and dose-dependent cytotoxicity to both leukemia and human bone marrow derived HPC. To examine whether complete cell kill can be achieved exclusively via the differentially expressed suicide gene plus ganciclovir in human leukemia cells, cells were transduced with recMCVtk or recMCVLuc, and ganciclovir Fig 3a and b) . However, only recMCVtk in conjunction with ganciclovir accomplished complete cell kill at virus particles of 10 per leukemia cell (Po.000001) (Fig 3a-c) . At this dose, the acute direct vector related cytotoxicity was only modest (without ganciclovir) and comparable to results depicted in Figure 2 . Leukemia cells transduced with luciferase encoding recMCVLuc survived whether ganciclovir was present or not and in this group only dose-dependent decreases in colonies were found as expected from acute vector toxicity similar to acute toxicity seen with recMCVtk (Fig 3a and b) . Data obtained in other cell lines (MB02, K562, and U937) were very similar (not shown).
recMCVtk encoding the HSV-tk suicide gene under control of the RSV promoter fails to deliver specific tk-mediated cytotoxicity in primary human HPC
To evaluate whether recMCVtk could cause specific tk-mediated cytotoxicity in human HPC, dose-response experiments were conducted. Both CD34 þ selected primary human peripheral blood stem cells (four individual donors) as well as primary bone marrow cells (four individual donors) were transduced with recMCVtk, cultured with or without ganciclovir for 3 days and then plated for colony formation. No significant difference in cytotoxicity was seen between groups with or without Figure 3 A RSV promoter controlled herpes simplex thymidine kinase (tk) encoding recombinant molecular conglomerate vector (recMCV) confers specific toxicity to leukemia cells but not to primary human bone marrow precursors. Leukemia cell lines M07e, THP1 were transduced with increasing doses of recMCV-tk purging of leukemia cells (tk) or the luciferase encoding control vector recMCV-Luc (Luc) (a,b). Groups were divided into ganciclovir (GCV) vs. no GCV treatment. Meg-01 and KG1 cells were not treated with the luciferase control construct (c). Following treatment, leukemia cells were plated for CFU-L formation, which are plotted against adenovirus particle number. Data represent the mean of quadruplicate points. CD34 þ selected human bone marrow cells from individual single donors were treated identically with recMCV-tk and recMCV-luc in separate experiments, and plated for mixed colony formation (CFU-GM CFU-GEMM), with the mean of the results plotted against adenovirus particle number (d). Data are the combined results from four individual bone marrow derived donors. Asterisks indicate a P-value of .05 or less.
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ganciclovir as determined by colony formation. Cytotoxicity with recMCVLuc was identical to the cytotoxicity observed with recMCVtk without ganciclovir (data not shown). While transduction with a concentration of 12.5 Â 10 6 adenovirus particles of recMCVtk vector followed by ganciclovir incubation caused complete cell kill in all leukemia cells tested (Fig 3a-c) , cytotoxicity to primary bone marrow cells from each individual donor tested was approximately 60%. Data presented are combined from four bone marrow derived donors (Fig  3d) . A separate experiment using CD34 þ selected peripheral blood stem cells from four individual donors yielded identical results, and no differences were seen in the viability assays when bone marrow derived or peripheral blood derived CD34 þ selected progenitor cells were studied (data not shown). These data suggest a favorable therapeutic index for this purging concept.
recMCVtk encoding the HSV-tk suicide gene under control of the RSV promoter effectively kills primary, chemotherapy refractory human leukemia cells
To proof that this therapeutic concept could also potentially be suitable in a clinical setting and capable of killing primary, patient derived human leukemia cells, experiments were conducted with primary human leukemia cells that were obtained through cytapheresis from two different patients suffering from chemotherapy refractory leukemia. One patient had CML in blast crisis (CML-blast), the other patient relapsed acute lymphoblastic leukemia (ALL). Complete cell kill of both primary cells was accomplished at 10 Â 10 6 virus particles with 50 mmol ganciclovir using 7-AAD viability staining (Fig 4a and b) . Under the same conditions, cytotoxicity of approximately 60% in CD34 þ selected primary human progenitor cells is observed using colony forming assays (Fig 3d) . Experiments were performed in quadruplicate and repeated in four separate experiments with similar outcomes.
Genetically marked human leukemia cells can be accurately discriminated from primary human hematopoeitic cells in mixed culture
Experiments were conducted to investigate whether genetically altered, EGFP expressing human leukemia cells could be used to discriminate those in mixed culture from normal human hematopoietic cells by using UV light microscopy. The left column of Figure 5 depicts images obtained by transmission light microscopy (image 5-1a-5-5a), the right column of Figure 5 depicts the same image under UV light (image 5-1b-5-5b). As EGFP expressing cells will fluoresce and corresponding cells seen on the a-labeled images can be identified under UV light in the b-labeled images, non-EGFP expressing cells seen under normal light will not be visible in b-labeled images. Normal bone marrow derived progenitor cells in semisolid agar are depicted under normal transmission light microscopy (Fig 5-1a) and UV (Fig 5-1b) . Meg-01-EGFP cells are depicted in (Fig 5-5b) . To demonstrate whether the purging strategy is capable in selectively killing contaminating leukemia cells from primary human hematopoietic cell preparations, CD34 þ selected human bone marrow cells were admixed with 10% EGFP expressing THP1-EGFP or Meg-01-EGFP. This allowed accurate identification and discrimination of fluorescing leukemia cells and their colonies from normal hematopoietic colonies. After transfection with Figure 4 A RSV promoter controlled herpes simplex thymidine kinase (tk) encoding recombinant molecular conglomerate vector (recMCV) confers specific toxicity primary, chemotherapy refractory human leukemia cells. Primary human leukemia cells were obtained through cytapheresis from two patients with refractory leukemia who previously had failed chemotherapy. One patient was in blast crisis with chronic myelogenous leukemia (CML-Blast), another patient had acute lymphocytic leukemia (ALL). Cytotoxicity was assessed by 7-AAD staining. Data represent the mean of quadruplicate points and represent one of three independent experiments. Asterisks indicate a P-value of .05 or less.
Purging of leukemia cells W Huang et al Purging of leukemia cells W Huang et al recMCVtk, cells were incubated with ganciclovir for 3 days and then plated for colony formation. Cells were plated for identification of normal primary human colonies (CFU-GM, GEMM) and separately, leukemia colonies (CFU-L). While large numbers of green fluorescent leukemia colonies were observed in control groups (no vector plus ganciclovir, vector without ganciclovir), no green colonies or CFU-L were identified in the treatment group (recMCVtk plus ganciclovir). Only normal hematopoietic colonies were seen. Under standard conditions, 27.3 normal and 165 fluorescent colonies were scored for Meg-01 contaminated progenitors, and in THP1 contaminated experiments 44.3 normal and 240 green fluorescent colonies were scored. Following the purging procedure 6.9 and 7.1 normal colonies without detection of any green fluorescing colonies were scored for Meg-01 and THP1 contaminated experiments, respectively. This indicates a progenitor cell toxicity of the purging procedure of 72 and 84%, respectively. No green fluorescing cells were detected by flowcytometry after treatment with recMCVtk plus ganciclovir (Fig 6a and b) . Flowcytometric analysis for cells obtained from a Meg-01 purging experiment is depicted in Figure 6c .
Discussion
Previous gene therapy based purging strategies have investigated adenovirus as a vector for the selective removal of solid tumor cells from stem cell preparations. The primary rationale for this approach was that adenovirus infected hematopoietic cells poorly, while epithelial tumor cell are susceptible to adenovirus infection. 13, 10 This restricted tropism precluded this concept's use for purging leukemia cells. 13 Effectiveness of this strategy was further refined by incorporation of a breast cancer specific promoter. 9, 11 In an effort to develop a suitable strategy to purge leukemia cells from HPC, we proposed to develop an MCV, which would be capable of effectively transducing both leukemia cells and primary HPC. 12 On the other side, such a tropism independent vector may also deliver equal toxicity to both normal and leukemia cells, thus killing HPC at similar efficacy as it would kill malignant cells abating a potential therapeutic effect. Therefore, to improve the therapeutic index, features needed to be introduced that would permit the upregulation of gene expression preferentially in leukemia cells or in its selective downregulation in HPC.
Tropism independence is accomplished by introduction of the polycation polylysine into the MCV. Polylysine binds to heparan receptors and via its positive charges adheres to cell membranes. 28, 29 We found that the latter mechanism is critical for the initial attachment of the vector to cell membranes. 12 Likewise, conjugation of polylysine with recombinant adenovirus overcomes natural tropism barriers, and with this modification, effective recombinant adenovirus transduction of hematopoietic cells can be accomplished. 12, 20 However, similar to most gene transfer vectors, polylysine constructs also exert a dose-dependent cytotoxicity. One concern with this system was that excessive vector concentrations causing acute vector related toxicity to HPC may be needed to deliver sufficient copies of the therapeutic gene in order to achieve complete kill of leukemia cells. Therefore, a critical requirement of any vector system is that gene transfer would be achieved with a vector sufficient for complete leukemia cell kill, while sparing HPC from both acute vector toxicity and the specific transgene-related cytotoxicty. This requirement is identical to conventional chemotherapy based ex vivo purging methods or in vivo therapies, where preferential cell kill of malignant cells is sought with minimal harm to normal tissue. Zarrin et al 30 previously have reported a comparative gene expression study using CMV, RSV and SV40 promoter driven constructs in lymphoid and myeloid leukemia cell lines where similar to our observations, highest gene expression was achieved with CMV driven constructs. Our initial experiments were designed to evaluate whether promoter related expression differences existed between primary CD34 þ selected HPC and a panel of different leukemia cell lines. The results indicated that while CMV could drive robust transgene expression in both normal CD34 þ selected HPC and all leukemia cells tested, RSV and SV40 driven transgene expression occurred only in leukemia cells. Given the enhanced expression levels with RSV, this promoter was selected for the design of a suicide gene-encoding construct.
To investigate selective cytotoxicity between normal and malignant hematopoietic cells, a recMCV encoding HSVtk under RSV control was constructed (recMCV-tk), which compared to MCV, greatly improved gene expression characteristics. 20 Enhanced gene expression per vector unit will likely reduce total vector required for leukemia cell kill, and consequently reduce acute vector related toxicity, and thus improve the therapeutic index. Although toxicity studies were performed with the tk gene as transgene, it is likely that recMCV constructs utilizing other transgenes may exert different toxicity profiles because different cytotoxicity of their products, which is irrespective of the presence of a prodrug such as GCV.
The results demonstrated that specific and complete kill of all leukemia cell lines examined as well as of two primary human leukemia cells derived from chemorefractory patients can be accomplished using HSV-tk/ GCV as a therapeutic gene. Despite the fact that the primary cells had been obtained from patients who had failed prior chemotherapy and therefore were labeled chemo-refractory, they were equally susceptible to this approach at similar vector concentrations as the cell lines. In one previously published study where adenovirus was used for purging of myeloma cells, the transduction efficiency was 80%, only reducing contaminating cells and failing to completely eradicating them. 15 In contrast, the recMCV-tk system consistently completely eradicated malignant leukemia cells in our experiments. More importantly, this could be accomplished at vector doses causing only moderate toxicity to HPC, and the method permitted complete and selective elimination of leukemia cells admixed to HPC cultures. This can be attributed to the universal tropism of polylysine, and the transgene's selectively restricted expression in leukemia cells. Although polylysine based constructs enter HPC as previously published by our group, failure of expression of the transgene under the RSV promoter protects these cells from cytotoxicity. 12, 14 Although the acute vector related toxicity still reduced significantly surviving progenitor cell numbers, most stem cell harvests provide excess HPC needed for aut-BMT. Near complete hematopoietic ablation is the goal of current hematologic malignancy treatment protocols and hematopoietic recovery depends on self-renewal and proliferation of Purging of leukemia cells W Huang et al residual HPC. Compared to conventional in vivo or ex vivo chemotherapy based cytotoxic leukemia treatments where normal hematopoietic cells are routinely reduced to less than 1% of its normal cellular mass in order to eliminate malignant cells, the described gene transfer based approach achieves complete elimination of cancerous cells at a significantly reduced toxicity. Using the fluorescent leukemia cell lines Meg-01 and THP-1 contaminating selected human progenitor cells, and complete elimination of the leukemia cells was accomplished, colony forming ability of normal hematopoietic colonies was reduced by 72-84%. It is likely that further optimization of this purging procedure could further reduce procedure associated toxicity.
Although MCV systems are excellent tools for proof of principle experiments, they are labor intensive and require extensive standardization for each lot manufactured. Enhanced tropism recombinant adenovirus vectors could possibly simplify and standardize the procedure. Since HSV-tk suicide gene therapy requires several days of ex vivo culture to become effective, other, faster acting toxin genes should be investigated as they may reduce the required ex vivo culture time. The end points in our studies were leukemia cell cytotoxicity and survival of a particular progenitor cell type phenotypically classified by CD34 þ expression and selection. Although CD34 þ progenitor cells are clearly cells with the ability to reconstitute humans after myeloablation and also with self-renewal capacity, and for this reason are being used extensively in clinical transplantation settings, recent data suggest that there may even be more primitive cells among CD34À/dull populations. [31] [32] [33] [34] As surrogate end point for viability and survival of HPC in vitro studies (CFU) were used. Additional studies are planned to better define the impact of purging on HPC repopulating abilities as well as different HPC subpopulations using in vivo experimental models. Moreover, by exploring polylysine encoding recombinant adenovirus we anticipate to significantly reduce the toxicity seen with the conjugate constructs, which would reduce the quantity of cells needed to be harvested for transplantation.
Although the clinical value for purging in auto-BMT remains still somewhat controversial, the development of novel tools to obtain stem cell preparations free of cancer cells remains a desirable goal in the field. The concept of minimal residual disease being a favorable prognostic indicator for malignancies is widely accepted. Moreover, minimal tumor burden may enhance the effectiveness of evolving immunotherapy and cancer vaccine strategies, and therefore, more effective purging strategies may become an integral part of innovative novel therapies for hematologic malignancies.
